Please ensure Javascript is enabled for purposes of website accessibility

This Was the Biggest, Most Overvalued Health-Care Buyout This Week

By Rich Smith - Apr 25, 2013 at 1:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you profited from it, congratulations. Now cash out.

The megabillion-dollar buyout of Life Technologies (NASDAQ: LIFE) by Thermo Fisher Scientific (TMO 5.97%) grabbed a lot of headlines earlier this week. Fool contributor Rich Smith, however, has a different story to tell.

It's the story of one overpriced company buying another company that's an even worse bargain, which resulted in a medical equipment behemoth that's even more egregiously overpriced than the two companies were separately.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Thermo Fisher Scientific Inc. Stock Quote
Thermo Fisher Scientific Inc.
TMO
$572.35 (5.97%) $32.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.